tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

GH Research initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of GH Research (GHRS) with an Outperform rating and $31 price target The firm says the “dramatic” antidepressive effects observed in the Phase IIb study of GH001, the company’s psychedelic with “many favorable properties” facilitating administration and delivery, should be replicable in Phase III and position the drug as a treatment of choice in the future paradigm. With the stock off its post-data highs, RBC sees a “compelling entry point.” While the stock’s major near-term catalysts may be more limited, there should be appreciation as GH’s development progress ensues and enthusiasm for psychedelics continues to build, contends the firm.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1